Silo Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. (Nasdaq: SILO) on September 29, 2025, regarding a material definitive agreement entered into on that date. The transaction involves a private placement of equity securities that closed on October 1, 2025.
Key Financial Metrics and Transaction Details
- Securities Sold: 2,857,143 shares of Common Stock.
- Offering Price: $0.875 per share.
- Gross Proceeds: Approximately $2.5 million (prior to fees and expenses).
- Warrants Issued: One unregistered warrant per share purchased, exercisable at $0.75 per share, expiring five years after the effective date of the resale registration statement.
- Placement Agent Fees: 7.5% cash fee plus 1.0% management fee on gross proceeds.
- Placement Agent Warrants: Warrants to purchase up to 214,285 shares (7.5% of aggregate shares sold) at an exercise price of $1.0938 per share.
- Expenses: Reimbursement of $25,000 for non-accountable expenses, $50,000 for legal/out-of-pocket expenses, and $15,950 for clearing fees.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Restrictions
The filing discloses a significant capital raise event. The Company is subject to a 30-day lock-up period from the Closing Date during which it cannot issue or announce the issuance of Common Stock or Common Stock Equivalents. Additionally, the Company is prohibited from entering into Variable Rate Transactions for one year following the Closing Date, subject to limited exceptions.
Outlook, Risks, and Contingencies
The Company has agreed to file a resale registration statement on Form S-3 within 15 calendar days of the Purchase Agreement date and use commercially reasonable efforts to have it declared effective within 75 calendar days. The filing notes that representations and warranties in the Purchase Agreement are for the benefit of the parties and may apply different materiality standards than those viewed by stockholders. The filing does not provide specific forward-looking guidance on revenue or profitability beyond the intended use of proceeds.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting the 8.5% total cash fees and other reimbursable expenses.
- Confirm the dilution impact of the 2,857,143 new shares plus the potential issuance of 2,857,143 warrant shares and 214,285 placement agent warrant shares.
- Monitor the status of the resale registration statement for the Warrant Shares to ensure liquidity for investors.
- Review the Company's cash position to assess the runway provided by the $2.5 million gross proceeds.